Original Article

(Check for updates



Brain & NeuroRehabilitation

Seung Don Yoo, Hyun Haeng Lee

HIGHLIGHTS

- We used a top-down approach to reduce the heterogeneity of the results of meta-analyses and used it to determine the methodology for literature selection and statistical analysis.
- In the results of meta-analysis, we found that RAAT had significant superiority over CT in improving arm function (standardized mean difference [SMD], 0.63; 95% confidence interval [CI], 0.37–0.88; p < 0.001; I² = 84%) and ADL (SMD, 0.24; 95% CI, 0.05–0.43; p = 0.010; I² = 27%).
- Through results of the meta-analysis, we found that RAGT, had a significant superiority over CT in improving balance (MD, 2.47; 95% CI, 0.41–4.53; p = 0.020; I² = 50%), but no significant superiority was identified in improving gait function (SMD, 0.22; 95% CI, -0.07 to 0.52; p 0.140; I² = 38%) and ADL (SMD, 0.17; 95% CI, -0.04 to 0.38; p = 0.11; I² = 0%).



Received: Jun 21, 2023 **Revised:** Aug 23, 2023 **Accepted:** Aug 31, 2023 **Published online:** Sep 20, 2023

Correspondence to

Hyun Haeng Lee

Department of Rehabilitation Medicine, Konkuk University School of Medicine and Konkuk University Medical Center, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, Korea.

Email: dr.hyunhaenglee@gmail.com



Original Article

(Check for updates

The Effect of Robot-Assisted Training on Arm Function, Walking, Balance, and Activities of Daily Living After Stroke: A Systematic Review and Meta-Analysis

Seung Don Yoo,¹ Hyun Haeng Lee²

¹Department of Rehabilitation Medicine, Kyung Hee University College of Medicine, Seoul, Korea ²Department of Rehabilitation Medicine, Konkuk University College of Medicine, Seoul, Korea

ABSTRACT

This meta-analysis aimed to compare the effects of robot-assisted training (RAT) with those of conventional therapy (CT), considering the potential sources of heterogeneity in the previous studies. We searched three international electronic databases (MEDLINE, Embase, and the Cochrane Library) to identify relevant studies. Risk of bias assessment was performed using the Cochrane's Risk of Bias 1.0 tool. The certainty of the evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations method. The meta-analyses for each outcome of the respective domains were performed using 24 randomized controlled trials (RCTs) on robot-assisted arm training (RAAT) for arm function, 7 RCTs on RAAT for activities of daily living (ADL), 12 RCTs on robot-assisted gait training (RAGT) for balance, 6 RCTs on RAGT for walking, and 7 RCTs on RAGT for ADL. The random-effects model for the meta-analysis revealed that RAAT has significant superiority over CT in improving arm function, and ADL. We also showed that RAGT has significant superiority over CT in improving balance. Our study provides highlevel evidence for the superiority of RAT over CT in terms of functional recovery after stroke. Therefore, physicians should consider RAT as a therapeutic option for facilitating functional recovery after stroke.

Keywords: Robotics; Upper Extremity; Lower Extremity; Recovery of Function; Stroke Rehabilitation

INTRODUCTION

Stroke is the primary cause of death and long-term disability worldwide in stroke survivors [1-3]. A significant proportion of stroke survivors have limited use of the affected upper and lower limbs. According to previous studies, upper limb deficits persist for 6 months after stroke onset in 30%–66% of patients with hemiplegia [4,5]. Cohort studies have revealed that 22% of patients with stroke do not regain walking ability [6]. Therefore, restoring the function of the affected upper and lower limbs after a stroke is of clinical importance.

OPEN ACCESS

Received: Jun 21, 2023 Revised: Aug 23, 2023 Accepted: Aug 31, 2023 Published online: Sep 20, 2023

Correspondence to Hyun Haeng Lee

Department of Rehabilitation Medicine, Konkuk University School of Medicine and Konkuk University Medical Center, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, Korea.

Email: dr.hyunhaenglee@gmail.com

Copyright © 2023. Korean Society for Neurorehabilitation

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Funding

None.

Conflict of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Yoo SD, Lee HH; Data curation: Yoo SD, Lee HH; Formal analysis: Yoo SD, Lee HH; Investigation: Yoo SD, Lee HH; Methodology: Yoo SD, Lee HH; Project administration: Lee HH; Resources: Yoo SD,





Lee HH; Software: Lee HH; Supervision: Lee HH; Visualization: Lee HH; Writing - original draft: Lee HH; Writing - review & editing: Yoo SD, Lee HH. Robot-assisted training (RAT) enables highly repetitive, adaptive, quantifiable, and taskspecific training with feedback for enhancing brain neuroplasticity [7,8]. RAT may also have an advantage over conventional therapies (CTs) due to its potential to motivate patients [9]. Several previous meta-analyses have demonstrated that robot-assisted arm training (RAAT) is significantly more effective than nonrobotic therapy and therapist-mediated training in restoring upper extremity function, strength, and performance in activities of daily living (ADL) after stroke [10-12]. Previous studies demonstrated that robot-assisted gait training (RAGT) have positive effects on gait speed, gait independence, and balance recovery after stroke [13-15]. Therefore, RAT for restoring upper and lower limb motor deficits and subsequent functional decline following stroke has been applied worldwide in clinical settings [16]. In accordance with accumulated evidence of the therapeutic effectiveness of RAT, the Health Insurance Review and Assessment Service in South Korea has, as of February 2022, established a selective health benefit for RAGT in patients with stroke and gait disturbance above a certain level.

However, the results of the meta-analyses presented in the aforementioned studies exhibited a high level of heterogeneity [10,12-15,17], making it difficult to generalize the effect of RAT. Therefore, in this study, we aimed to compare the effects of RAAT and RAGT with those of CT through a meta-analysis, considering the potential sources of heterogeneity among studies that demonstrated the effectiveness of RAT.

MATERIALS AND METHODS

The protocol used in this study was determined before performing meta-analyses as a part of the development of the Clinical Practice Guideline for Stroke Rehabilitation in Korea. Part 1: Rehabilitation for Motor Function (2022) [18]. The protocol was not registered on a formal registration website.

Strategies to minimize the heterogeneity of meta-analysis results and draw generalized statements about the effectiveness of RAT

To reduce the heterogeneity in the results of meta-analyses that confirm the effectiveness of RAT, we propose the following conditions that the meta-analysis should meet: 1) RAT and CT should be dose-matched. 2) Exclude studies in which RAT was combined with interventions other than CT, such as interventions providing RAT in a virtual reality environment, were excluded, because the effectiveness of RAT alone could not be estimated by pooling the results of those studies. 3) Despite two Cochrane reviews confirming the effectiveness of RAT, including preliminary and pilot studies [14,17], we chose to include only randomized controlled trials (RCTs) because we assumed that including such studies could introduce heterogeneity into the results of the meta-analysis. Furthermore, since crossover RCTs may have potential drawbacks compared to parallel RCTs, such as carryover, period, and sequence effects and period-by-treatment interactions [19], we planned to select only parallel RCTs for the meta-analysis in this study. 4) As the form and technological level of robots evolve, older studies risk diluting the therapeutic effects of contemporary robots. Therefore, we conducted a meta-analysis of studies published after 2000.

To draw statements about the generalized effectiveness of robotic therapy from the results of the meta-analysis in this study, we considered the following: 1) inclusion of studies in which RAT was administered both alone and in conjunction with CT, 2) comprehensive inclusion of



metrics for each of the following domains: arm function, balance, walking, and ADL, and 3) use of a random-effects model for the meta-analysis to deal with between-study variance [20] which reflects the heterogeneity of the environment in which the RAT is provided.

Literature selection

Search strategy

Utilizing previous meta-analyses and clinical practice guidelines [10-15,21,22], we identified and collected search terms presented elsewhere [18]. Six information search experts conducted a literature search using three overseas databases: the PubMed (https:// pubmed.ncbi.nlm.nih.gov/), EMBASE (http://embase.com), and Cochrane Library (http:// cochranelibrary.com). We conducted a comprehensive literature search for articles published before February 28, 2022. Literature selection was based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement, which is presented in **Fig. 1**. The search was limited to articles published in English.




Fig. 1. PRISMA flow chart.



Inclusion and exclusion criteria

Two reviewers (Y.S.D and L.H.H) independently reviewed the screened literature using our own Population, Intervention, Comparison, Outcomes and Study (PICOS) framework, which reflected the above strategies.

Population: We selected studies that enrolled patients with stroke onset age of 18 years and older and upper or lower limb dysfunction due to stroke.

Intervention: We defined RAT as "the application of electronic and computerized control systems to mechanical devices designed to assist human functions in rehabilitation," which was used in a previous study [10].

Comparison: RAT (add-on or alone) vs. CT

We set the conditions for comparability between interventions as follows: 1) the duration of therapy provided in the RAT and CT groups should be the same and 2) in studies where RAT is provided as an add-on therapy, treatments other than RAT in the experimental group must have the same form as those in the CT group, and the total duration of therapy in the RAT group should be the same as that in the CT group.

Outcome: We included studies that assessed each of the following domains using relevant endpoints: arm function, balance, walking, and ADL.

- 1) Arm function: Manual Function Test, Fugl-Meyer Assessment, Box and Block Test, Action Research Arm Test, Wolf Motor Function Test, and 9-Hole Peg Test
- 2) Balance: Berg Balance Scale
- 3) Walking: 10 Meter Walk Test, gait speed (average or maximum, m/s), 6 Minute Walk Test
- 4) ADL: Functional Independence Measure, Barthel Index, Modified Barthel Index, Korean version of the Modified Barthel Index, Frenchay Activities Index, Frenchay Arm Test, and Motor domain of Functional Independence Measure

We did not use outcomes obtained through patient-reported or subjective measures, which pose a potential risk of bias in the meta-analysis. Because numerous factors can influence the long-term effects of an intervention, we included studies with functional outcomes immediately after the intervention as the primary endpoint.

Study design: parallel RCT

As stated previously, we did not include studies that combined RAT with other interventions such as virtual reality and functional electrical stimulation. Two reviewers (Y.S.D, and L.H.H) independently screened potentially eligible studies by manually reviewing titles and abstracts, and assessed eligibility through full-text screening. Disagreements were resolved through discussion when necessary.

Risk of bias assessment

Two reviewers (Y.S.D and L.H.H) independently evaluated the methodological quality of the included RCTs using the Cochrane Risk of Bias 1.0 tool and resolved any disagreements by discussion.

Data extraction and transformation

If a study presented multiple outcomes for the same domain, we ranked the outcomes for each



domain according to their order in the preceding list and used the highest-ranking outcome for the meta-analysis. The two reviewers reached mutual agreement on whether to use the post-intervention outcome or the difference in outcomes (calculated by subtracting the pre-intervention (baseline) outcome from the post-intervention outcome) for the respective domains (Y.S.D, and L.H.H). When the study did not directly provide the difference in outcome, we used the mean and standard deviation of both the post-intervention and preintervention (baseline) results to compute the mean and standard deviation of the outcome change, following the formula given in the Cochrane Handbook [23]. Studies with more than two intervention groups or if outcomes for continuous variables were not presented as means and standard deviations, they were converted to values to be pooled using a valid method, as described in the handbook. We excluded the studies in which no endpoints were obtainable for inclusion in the meta-analysis using the aforementioned procedure.

Assessment of certainty of evidence

The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method [24] into high, moderate, low, or very low. We used five considerations (risk of bias, imprecision, inconsistency, indirectness, and publication bias) of the GRADE for the selected RCTs [24]. When evaluating the imprecision item in GRADE, we verified whether the total number of study participants in each domain met the criterion for optimal information size. Both authors independently performed the entire procedure and reached a consensus.

Statistical analysis

The previously outlined strategies were also embodied in our statistical analysis methodology. We conducted an intention-to-treat analysis in which all the participants who were initially randomized were included in the analyses according to the groups to which they were assigned. The effect of RAT on the outcomes of each functional domain was assessed using the pooled standardized mean difference (SMD). In cases in which a singular type of outcome was drawn for a particular domain, MD was used. To account for the variability between studies, we used a random-effects model to calculate the pooled SMD for the outcomes of each functional domain, along with their corresponding 95% confidence intervals. Defining an I² statistic \geq 50 as statistical heterogeneity of the respective meta-analyses, following the same criteria as that of the previous study [10] and the Cochrane Handbook [23], we performed a subgroup analysis when the results of the meta-analysis showed statistical heterogeneity. We performed the subgroup analysis based on stroke chronicity, which was set at 3 months after onset, similar to the criterion in the Cochrane review [11,14]. While previous studies have performed subgroup analysis based on the type of robot and the part of the body trained [12], we did not perform further subgroup analysis to ensure the generalizability of the effects of the RAT and to avoid the risk of Type I error elevation due to multiple comparison. To evaluate the risk of publication bias in the results of the respective meta-analyses, we inspected the funnel plots for comparisons using more than 10 studies. The meta-analysis was performed using RevMan 5.2 (Nordic Cochrane Centre, Copenhagen, Denmark). The statistical significance was set at p < 0.05.

RESULTS

Based on the aforementioned criterion, we successfully identified 29 studies on the effectiveness of RAAT and RAGT. The results of the risk of bias assessment for the 58 studies






Fig. 2. Risk of bias summary for all selected literatures.

are presented in **Fig. 2**. We decided to use the changes in the arm function and ADL domain outcomes because we found significant differences in the baseline values of the outcomes between the two groups in the selected literature on RAAT. We also chose to use the change in outcome because there were notable differences in the baseline values for the balance and walking domains between the two groups in the selected literature on RAGT. The baseline values of the outcomes corresponding to the ADL domain were relatively homogeneous; therefore, we decided to use the post-intervention outcomes. After excluding studies that were rated as "high risk" in four or more domains of the risk of bias assessment and those that did not provide suitable endpoints for meta-analysis, we included 25 RAAT [25-49] and 16 RAGT [50-65] studies in the meta-analysis, which are detailed in **Supplementary Table 1**.

We found that RAAT had significant superiority over CT in improving arm function (SMD, 0.63; 95% confidence interval [CI], 0.37–0.88; p < 0.001; I² = 84%) and ADL (SMD, 0.24; 95% CI, 0.05–0.43; p = 0.010; I² = 27%) (**Figs. 3** and **4**). The meta-analysis of arm function showed a significant level of heterogeneity between studies, with an I² of 84%; therefore, we conducted a subgroup analysis based on the criterion of 3 months since stroke onset (**Fig. 5**). There were six studies that only recruited patients with stroke chronicity < 3 months, and the meta-analysis found a significant superiority (SMD, 0.41; 95% CI, 0.06–0.75; p = 0.02, I² = 58%) of RAT over CT. There were 10 studies that only included patients with stroke chronicity > 3 months, and the meta-analysis also found a significant superiority of RAT over CT (SMD, 0.80; 95% CI, 0.26–1.33; p = 0.004, I² = 84%), but the heterogeneity between studies was not resolved. In the meta-analysis of ADL, the heterogeneity between studies was low, with I² of 27%. The quality of evidence was judged to be 'high,' as there were no downgrades in the GRADE assessment for all outcome measures in each domain.

The meta-analysis revealed that RAGT had a significant superiority over CT in improving balance (MD, 2.47; 95% CI, 0.41–4.53; p = 0.020, I² = 50%), but no significant superiority was identified in improving gait function (SMD, 0.22; 95% CI, -0.07 to 0.52; p = 0.140; I² = 38%) and ADL (SMD, 0.17; 95% CI, -0.04 to 0.38; p = 0.11; I² = 0%) (**Figs. 6**, **7**, and **8**). The I² of the meta-analysis for balance was 50%, showing some heterogeneity between studies; therefore, we performed a subgroup analysis based on the criterion of 3 months since stroke onset (**Fig. 9**). Three studies recruited patients with stroke chronicity < 3 months, and the meta-analysis of these studies had an I² of 7%, indicating a homogeneous selection of studies. The meta-analysis found a significant superiority (SMD, 5.75; 95% CI, 1.72–9.79; p = 0.005; I² = 7%) of RAT over CT. Three studies recruited only patients with stroke chronicity >3 months, and the meta-analysis of these studies had an I² of 0%, implying a homogeneous selection of studies; however, there was no significant superiority of RAT over CT (SMD, -0.62; 95% CI, -2.55 to 1.34; p = 0.51; I = 0%). The results of the meta-analysis of gait function and ADL showed relatively low heterogeneity between studies. The quality of evidence was judged to be 'high,' as there



	Ex	perimenta			Control			itd. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
1.1.1 Arm function										
Aprile 2020	8.5	8.15	123	8.57	8.15	124	5.7%	-0.01 [-0.26, 0.24]	+	
Budhota 2021	4.41	2.1661	22	3	2.19136	22	4.4%	0.64 [0.03, 1.24]		
Calabrò 2019	7	1.2609	25	4	1.19289	25	3.9%	2.41 [1.67, 3.15]		
Dehem 2019	19.5	8.2964	23	10.8	7.89847	22	4.4%	1.05 [0.43, 1.68]		
Franceschini 2020	11	3.2999	25	-1	5.09094	23	3.7%	2.78 [1.97, 3.59]		
Frisoli 2022	11.1	13.9	13	8.9	17.6	13	3.8%	0.13 [-0.64, 0.90]		?? 🗣 ? 🗣 ? 🗣
Housman 2009	3.3	2.4	17	2.2	2.6	17	4.2%	0.43 [-0.25, 1.11]		
Kim 2021	2.52	5.48	23	1.17	4.18	24	4.6%	0.27 [-0.30, 0.85]		
Lee 2016	1.64	1.53	29	1.23	1.8	29	4.8%	0.24 [-0.27, 0.76]	·	
Liao 2012	6.3	1.9876	10	1.3	2.95242	10	2.8%	1.90 [0.81, 3.00]		
Lo 2010	3.87	1.05	49	4.01	1.06	50	5.2%	-0.13 [-0.53, 0.26]		~ ~~~~~~~~
Lum 2002	4.7	1.2	15	3.1	0.8	15	3.6%	1.53 [0.70, 2.35]		+?++ + ? +
Lum 2006	6.92	2.05	24	5.8	2.5	6	3.4%	0.51 [-0.40, 1.42]		??
Masiero 2007	15.8	8.1	17	10.3	12.1	18	4.2%	0.52 [-0.16, 1.19]	· · · · ·	?? • • • ? •
Masiero 2011	12.16	8.3	11	13.87	10.2	10	3.5%	-0.18 [-1.04, 0.68]		~?~~~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Masiero 2014	20	5.8175	16	14	6.6851	18	4.0%	0.93 [0.22, 1.64]		
Orihuela-Espina 2016	5.66	2.73	9	1.5	2.26	8	2.7%	1.57 [0.44, 2.69]		•?••
Ranzani 2020	7.14	5.72	17	6.85	5.34	16	4.2%	0.05 [-0.63, 0.73]		? • • • • • •
Rémy-Néris 2021	13.32	9.03	107	11.78	8.84	108	5.6%	0.17 [-0.10, 0.44]		
Rodgers 2019	8.2	5.7059	257	6	5.40973	254	5.8%	0.40 [0.22, 0.57]		
Sale 2014	17.15	10.4318	11	19.5	3.47669	9	3.4%	-0.28 [-1.16, 0.61]		~?~~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Timmermans 2014	4	4.5675	11	-1	3.38676	11	3.3%	1.20 [0.27, 2.12]		
Wu 2012	3.85	2.4931	14	4.21	2.05831	28	4.3%	-0.16 [-0.80, 0.48]		7666676
Xu 2020	6.7	2.4875	20	5	1.70667	20	4.3%	0.78 [0.14, 1.43]		? • • • • • ? •
Subtotal (95% CI)			888			880	100.0%	0.63 [0.37, 0.88]	•	
Heterogeneity: Tau ² = 0).27; Chi	² = 119.82	2, df =	23 (P <	0.00001)	$1^2 = 8$	1%			
Test for overall effect: Z										
Total (95% CI)			888			880	100.0%	0.63 [0.37, 0.88]	◆	
Heterogeneity: $Tau^2 = 0$).27; Chi	$^{2} = 119.82$	2, df =	23 (P <	0.00001)	$1^2 = 8$	1%			
Test for overall effect: Z									-4 -2 0 2 4	a
Test for subgroup differ									Favours [Control] Favours [Robotic therapy	1
Risk of bias legend										
(A) Random sequence g	eneratio	n (selectio	n bias)							
(B) Allocation concealm										

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias) (G) Other bias

Fig. 3. Effect of robot-assisted arm training on arm function after stroke. SD, standard deviation; CI, confidence interval.

	Exp	periment	al		Control		9	Std. Mean Difference		Std. Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% Cl	ABCDEFG
1.3.1 ADL											
Aprile 2020	23.87	18.76	123	22.98	18.76	124	28.9%	0.05 [-0.20, 0.30]			
Lee 2016	9.95	7.09	29	9.55	6.46	29	10.9%	0.06 [-0.46, 0.57]			
Lum 2006	2.85	1.22	24	3.2	1.4	6	4.1%	-0.27 [-1.17, 0.63]			??+++?
Masiero 2007	32.6	7.2	17	25.5	10.5	18	6.6%	0.77 [0.08, 1.46]			- ??���?\$
Masiero 2011	1.83	1.4	11	1	0.7	10	4.2%	0.71 [-0.18, 1.60]			— •?•••?•
Rodgers 2019	1	0.2774	257	0.9	0.3823	254	38.8%	0.30 [0.12, 0.47]			.
Villafañe 2018 Subtotal (95% CI)	22.8	2.4	16 477	21.6	2.4	16 457	6.4% 100.0%	0.49 [-0.22, 1.19] 0.24 [0.05, 0.43]		•	? ? 0 0 0 ? 0
Heterogeneity: Tau ²	= 0.02; 0	Chi ² = 8.2	24. df =	= 6 (P =	0.22); I ²	= 27%					
Test for overall effec	t: Z = 2.4	46 (P = 0	.01)								
Total (95% CI)			477			457	100.0%	0.24 [0.05, 0.43]		•	
Heterogeneity: Tau ²	= 0.02; 0	$Chi^2 = 8.2$	24, df =	= 6 (P =	0.22); I ²	= 27%			H	<u> t t t t t </u>	
Test for overall effec	t: $Z = 2.4$	46 (P = 0	.01)						-2	-1 0 1 Favours [Control] Favours [Robot	Z tis thoronyl
Test for subgroup di	fferences	Not an	licable							Favours [Control] Favours [Robol	tic therapy]

Test for subgroup differences: Not applicable

Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Fig. 4. Effect of robot-assisted arm training on activities of daily living after stroke.

SD, standard deviation; CI, confidence interval.



	Experimental						:	Std. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup	Mean		Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
1.2.1 Arm function ((<3mont	hs after s	troke)							
Dehem 2019	19.5	8.2964	23	10.8	7.89847	22	6.2%	1.05 [0.43, 1.68]		
Lee 2016	1.64	1.53	29	1.23	1.8	29	6.7%	0.24 [-0.27, 0.76]		
Masiero 2011	12.16	8.3	11	13.87	10.2	10	5.1%	-0.18 [-1.04, 0.68]		Θ
Masiero 2014	20	5.8175	16	14	6.6851	18	5.8%	0.93 [0.22, 1.64]		
Rémy–Néris 2021	13.32	9.03	107		8.84	108	7.7%	0.17 [-0.10, 0.44]		@?@@@?@
Sale 2014	17.15	10.4318	11	19.5	3.47669	9	5.0%	-0.28 [-1.16, 0.61]		9799979
Xu 2020	6.7	2.4875	20	5	1.70667	20	6.1%	0.78 [0.14, 1.43]		? 🛑 🗣 🗣 🤁 🗣
Subtotal (95% CI)			217			216	42.8%	0.41 [0.06, 0.75]	◆	
Heterogeneity: Tau ²				= 6 (P =	0.03); I ² =	58%				
Test for overall effect	t: Z = 2.3	B3 (P = 0.0)	2)							
1.2.2 Arm function (>3mont	hs after s	troke)							
Budhota 2021	4.41	2.1661	22	3	2.19136	22	6.3%	0.64 [0.03, 1.24]		
Calabrò 2019	7	1.2609	25	4	1.19289	25	5.7%	2.41 [1.67, 3.15]		99999? 9
risoli 2022	11.1	13.9	13	8.9	17.6	13	5.5%	0.13 [-0.64, 0.90]		?? •? •? •
Housman 2009	3.3	2.4	17	2.2	2.6	17	6.0%	0.43 [-0.25, 1.11]		$\Theta \Theta \Theta \Theta \Theta O O$
Liao 2012	6.3	1.9876	10	1.3	2.95242	10	4.2%	1.90 [0.81, 3.00]		
Lo 2010	3.87	1.05	49	4.01	1.06	50	7.3%	-0.13 [-0.53, 0.26]		Θ
Lum 2002	4.7	1.2	15	3.1	0.8	15	5.3%	1.53 [0.70, 2.35]		@?@@@?@
Masiero 2007	15.8	8.1	17	10.3	12.1	18	6.0%	0.52 [-0.16, 1.19]		??~~~~?~
Timmermans 2014	4	4.5675	11		3.38676	11	4.9%	1.20 [0.27, 2.12]		9999997
Wu 2012	3.85	2.4931	14	4.21	2.05831	28	6.1%	-0.16 [-0.80, 0.48]		? + + + + ? +
Subtotal (95% CI)			193			209		0.80 [0.26, 1.33]	-	
Heterogeneity: Tau ²				= 9 (P <	0.00001);	$1^2 = 8^4$	1%			
Test for overall effect	t: $Z = 2.9$	P = 0.0	04)							
Total (95% CI)			410			425	100.0%	0.61 [0.29, 0.93]	◆	
Heterogeneity: Tau ²	= 0.33; C	chi ² = 71.0)6, df =	= 16 (P	< 0.00001); $I^2 = 7$	77%		-4 -2 0 2 4	
Fest for overall effect	t: Z = 3.7	76 (P = 0.0)	002)						Favours [Control] Favours [Robotic therap	w]
Fest for subgroup dif	fferences	: Chi ² = 1.	42, df	= 1 (P =	= 0.23), I ^z	= 29.6	%		ratears peontering ratears (nobotic therap	
Risk of bias legend										
A) Random sequence	e generat	tion (select	tion bia	is)						
B) Allocation concea	lment (se	election bia	as)							
C) Blinding of partic	ipants an	d personn	el (per	formane	e bias)					
D) Blinding of outco	me asses	sment (de	tection	bias)						
D. I										

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Fig. 5. Subgroup analysis results of robot-assisted arm training on arm function according to the chronicity of stroke. SD, standard deviation; CI, confidence interval.

were no downgrades in the GRADE assessment for all outcome measures in the respective domains. We found no graphical evidence of publication bias in this meta-analysis (**Fig. 10**).

DISCUSSION

In the present study, we found that RAT was superior to CT in facilitating the recovery of several functional domains after stroke. The results of this meta-analysis are consistent with those of previous meta-analyses that found RAAT to be significantly superior to CT in restoring arm function and ADL performance after stroke [10,12,17,83]. The results of this meta-analysis are also consistent with those of previous meta-analyses showing a statistically significant superiority of RAGT over CT for balance [13,15], but are not consistent with those of previous meta-analyses showing a statistically significant superiority for gait [13,14]. The difference between the results may be attributed to the conditions proposed in this study to reduce the heterogeneity of the results of the meta-analysis and the additional conditions applied during the literature selection process. Mehrholz et al. [14] pooled the outcomes of gait independence, gait velocity, and walking capacity as the respective outcomes and found that RAT had an effect on the first two outcomes, but there was no significant effect on walking capacity. In contrast, in this study, we pooled all the results of these outcomes together in the walking domain.



	Ex	perimenta	I		Control			Mean Difference	Mean Difference Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI A B C D E F G
2.1.1 Balance									
Belas dos Santos 2018	5.8	10.4631	11	8.2	6.55966	8	5.2%	-2.40 [-10.07, 5.27]	
Hornby 2008	1	5.6711	31	2	4.92096	31	14.1%	-1.00 [-3.64, 1.64]	
Jayaraman 2018	11.3	13.6	27	7.3	7	27	7.5%	4.00 [-1.77, 9.77]	
Kim 2015	14.62	7.9775	15	7.23	4.02769	15	9.7%	7.39 [2.87, 11.91]	
Kim 2019	14.3	9.0703	28	9.6	6.7992	30	10.5%	4.70 [0.55, 8.85]	
Nam 2018	7	7.9904	20	4.25	8.88978	20	8.4%	2.75 [-2.49, 7.99]	
Nam 2020	2.89	10.391	20	2.1	5.80509	20	8.4%	0.79 [-4.43, 6.01]	
Palmcrantz 2021	2.69	6.5267	20	2.77	5.43708	17	11.2%	-0.08 [-3.94, 3.78]	
Park 2020	17.43	4.1871	7	9.85	4.43682	7	9.7%	7.58 [3.06, 12.10]	
Wall 2020	14	17.8126	17	14.5	11.6539	16	3.3%	-0.50 [-10.71, 9.71]	
Yeung 2021	18.8	13.31	14	14.4	11.66	17	4.1%	4.40 [-4.51, 13.31]	
Zhai 2021	3.6	7.83	10	3.3	4.64	10	7.7%	0.30 [-5.34, 5.94]	
Subtotal (95% CI)			220			218	100.0%	2.47 [0.41, 4.53]	\bullet
Heterogeneity: Tau ² =	6.02; Chi	$^{2} = 21.86$,	df = 1	1 (P = 0)).03); I ² =	50%			
Test for overall effect:	Z = 2.35	(P = 0.02)							
Total (95% CI)			220			218	100.0%	2.47 [0.41, 4.53]	▲
Heterogeneity: Tau ² =	6.02; Chi	² = 21.86,	df = 1	1 (P = 0	0.03); I ² =	50%			-20 -10 0 10 20
Test for overall effect:	Z = 2.35	(P = 0.02)							Favours [Control] Favours [Robotic therapy]
Test for subgroup diffe	rences: N	lot applica	ble						ratears (control, ratears (robotic (nerapy)
Risk of bias legend									

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Fig. 6. Effect of robot-assisted gait training on balance after stroke. SD, standard deviation; CI, confidence interval.

	Exp	periment	al		Control			Std. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
2.3.1 Walking										
Chua 2016	0.31	0.2403	53	0.4	0.47848	53	25.4%	-0.24 [-0.62, 0.15]		
Jayaraman 2018	34.6	20.9	27	29.5	22	27	18.0%	0.23 [-0.30, 0.77]		
Kim 2019	2	4.825	28	0.4	0.27592	30	18.5%	0.47 [-0.05, 0.99]		
Nam 2018	0.25	0.4362	20	0.12	0.91764	20	14.9%	0.18 [-0.44, 0.80]		
Taveggia 2016	0.28	0.08	13	0.21	0.1	15	10.9%	0.74 [-0.03, 1.52]		
Yeung 2021	0.32	0.41	14	0.17	0.38	17	12.3%	0.37 [-0.34, 1.09]		
Subtotal (95% CI)			155			162	100.0%	0.22 [-0.07, 0.52]	◆	
Heterogeneity: Tau ²	= 0.05; 0	Chi ² = 8.	09, df =	= 5 (P =	= 0.15); I ²	= 38%				
Test for overall effec	t: Z = 1.4	48 (P = 0)	.14)							
Total (95% CI)			155			162	100.0%	0.22 [-0.07, 0.52]	•	
Heterogeneity: Tau ²	= 0.05; (Chi ² = 8.	09, df =	= 5 (P =	= 0.15); I ²	= 38%				<u> </u>
Test for overall effec	t: Z = 1	48 (P = 0	.14)						Favours [Control] Favours [Robotic t	t heranvl
Test for subgroup di	fferences	s: Not ap	plicable	e					ravours [control] ravours [topotte t	incrup 7]
Risk of bias legend										
(A) Random sequenc	e genera	tion (sele	ection b	oias)						
(B) Allocation concea	alment (s	election	bias)							
(C) Blinding of partic	ipants ar	nd perso	nnel (pe	erforma	nce bias)					
(D) Blinding of outco	me asse	ssment (detectio	on bias)						
(E) incomplete outco	ma data	(attrition	hine)							

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Fig. 7. Effect of robot-assisted gait training on walking after stroke. SD, standard deviation; CI, confidence interval.

Subgroup analysis of arm function showed that RAAT was superior to CT regardless of chronicity, suggesting that RAAT can promote the recovery of arm function by providing repetitive and task-specific therapy, even in patients with chronic stroke. This is consistent with the results of a recent study that found a positive effect of RAAT over CT on arm function in the chronic phase over 3 months [83]. In the subgroup analysis of balance, the superior effect size of RAGT over CT was not statistically significant in the chronic phase of stroke. These results suggest that the degree to which RAGT affects balance is greater in the acute or subacute phase than in the chronic phase, which is consistent with previous research [15].



	Exp	eriment	al	с	ontrol		9	Std. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
2.4.1 ADL										
Chua 2016	71.2	19.4	53	72.2	22.7	53	29.8%	-0.05 [-0.43, 0.33]	+	~~~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Kim 2015	57.08	19.39	15	49.46	16.35	15	8.2%	0.41 [-0.31, 1.14]		? 😑 😔 ? 🕒 ? 🗣
Kim 2019	74.9	19.7	28	69.6	21.2	30	16.1%	0.26 [-0.26, 0.77]		••••••
Nam 2018	21.5	9.4	20	20.31	9.02	20	11.2%	0.13 [-0.49, 0.75]	- -	
Ochi 2015	13	5.93	13	13	3.7	13	7.3%	0.00 [-0.77, 0.77]		
Schwartz 2009	66.9	15.6	37	60.3	14.8	30	18.2%	0.43 [-0.06, 0.92]		? 🗧 🖶 🖨 🤶 ? 🗣
Wall 2020	60	16.67	17	57.5	14.81	16	9.2%	0.15 [-0.53, 0.84]		? 🗧 🖶 🖶 🖶 🖨
Subtotal (95% CI)			183			177	100.0%	0.17 [-0.04, 0.38]	•	
Heterogeneity: Tau ² =	= 0.00; C	$hi^2 = 3$.07, df	= 6 (P =	= 0.80);	$I^2 = 09$	6			
Test for overall effect	Z = 1.5	8 (P = (0.11)							
Total (95% CI)			183			177	100.0%	0.17 [-0.04, 0.38]	•	
Heterogeneity: Tau ² =	= 0.00; C	hi ² = 3	.07, df	= 6 (P =	= 0.80);	$ ^2 = 0$ %	6			- <u> </u>
Test for overall effect	: Z = 1.5	8 (P = (0.11)						-4 -2 0 2 Favours [Control] Favours [Robotic	4 thorapyl
Test for subgroup dif	ferences	: Not ap	plicabl	e					ravours [control] ravours [Robotic	. therapy
Risk of bias legend										
(A) Random sequence	e generat	ion (sel	ection	bias)						

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Fig. 8. Effect of robot-assisted gait training on activities of daily living after stroke. SD, standard deviation; CI, confidence interval.

	Ex	perimenta	ul 🛛		Control			Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
2.2.1 Balance (<3mont	ths after	stroke)								
Park 2020	17.43	4.1871	7	9.85	4.43682	7	17.4%	7.58 [3.06, 12.10]		
Wall 2020	14	17.8126	17	14.5	11.6539	16	6.0%	-0.50 [-10.71, 9.71]		? = = = = = =
Yeung 2021 Subtotal (95% CI)	18.8	13.31	14 38	14.4	11.66	17 40	7.5% 30.9%			
Heterogeneity: Tau ² = 1	1.14; Chi	$^{2} = 2.15, c$	f = 2 (P = 0.3	4); I ² = 7%				_	
Test for overall effect: Z	2 = 2.80	(P = 0.005))							
2.2.2 Balance (>3mont	ths after	stroke)								
Belas dos Santos 2018	5.8	10.4631	11	8.2	6.55966	8	9.3%	-2.40 [-10.07, 5.27]		
Hornby 2008	1	5.6711	31	2	4.92096	31	24.9%	-1.00 [-3.64, 1.64]		
Nam 2020	2.89	10.391	20	2.1	5.80509	20	15.1%	0.79 [-4.43, 6.01]		
Palmcrantz 2021	2.69	6.5267	20	2.77	5.43708	17	19.8%			
Subtotal (95% CI)			82			76	69.1%	-0.61 [-2.55, 1.34]	+	
Heterogeneity: Tau ² = (0.00; Chi	² = 0.64, d	lf = 3 (P = 0.8	(9); I ² = 0%					
Test for overall effect: Z	2 = 0.61	(P = 0.54)								
Total (95% CI)			120			116	100.0%	1.25 [-1.54, 4.03]	-	
Heterogeneity: Tau² = 6	5.28; Chi	² = 11.98,	df = 6	(P = 0.	.06); I ² = 5	0%			-20 -10 0 10	20
Test for overall effect: Z	Z = 0.88	(P = 0.38)							Favours [Control] Favours [Robotic	
Test for subgroup diffe	rences: C	$hi^2 = 7.75$, df = 1	1 (P = 0)	0.005), I ² =	87.1%			ravous (control) ravous (kobotik	(neiapy)
Risk of bias legend										

(A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Fig. 9. Subgroup analysis results of robot-assisted gait training on balance according to the chronicity of stroke.

SD, standard deviation; CI, confidence interval.

The underlying mechanisms by which the effects of RAAT on the recovery of arm function and RAGT on the recovery of balance are affected differently by the chronicity of stroke should be confirmed in future studies.

We used a top-down approach to reduce the heterogeneity of the results of the meta-analyses and determine the methodology for literature selection and statistical analysis. However, we found a substantial heterogeneity in the results of this meta-analysis. Various factors






Fig. 10. Funnel plots of comparison using ≥ 10 studies. SE, standard error; SMD, standardized mean difference; MD, mean difference.

> may have contributed to the heterogeneity. First, the heterogeneity of the meta-analyses may be attributed to the heterogeneity of the interventions. The manner in which RAT is delivered varies depending on the trial design (add-on vs. alone), robot type (end-effector vs. exoskeleton), training part (proximal vs. distal vs. both), and laterality (unilateral vs. bilateral), making it difficult to control the intervention [12], which is a common feature of rehabilitative therapies [84]. We also did not distinguish between varying levels of RAT intensity and duration across studies. Second, heterogeneity may occur when the results from assessment tools with different levels of construct validity, reliability, and responsiveness are pooled [85]. In this study, we measured arm function, balance, walking, and ADL using a variety of clinical assessment tools according to the respective domain, which corresponds to the construct in the context of measurement [86]. Because the four constructs cannot be measured directly, it is necessary to secure the validity, reliability, and responsiveness of the assessment tools that indirectly measure each construct so that the construct can be meaningfully correlated with the number obtained by the assessment tool [85]. Even metrics that measure the same construct reflect it to varying degrees, since those have distinct degrees of construct validity. This could be a source of heterogeneity when combining clinical assessment tool outcomes. Reliability encompasses internal consistency and test-retest, inter-rater, and intra-rater reliabilities, which refers to the precision or accuracy of measurement procedures [85,87]. Even if the same construct is



assessed using clinical assessment tools with the same level of construct validity, there will be heterogeneity in the outcomes if the reliability level of the measurement varies. Responsiveness refers to an instrument's ability to detect changes resulting from an intervention [87], including floor effects, ceiling effects, and minimal clinically important differences. When clinical assessment tools with varying levels of responsiveness to each construct are used, heterogeneity may occur during the pooling of outcomes, even when SMD is used. Additionally, the ceiling or floor effect of the instrument can result in skewed outcome distributions, which can lead to misleading results when the number of studies used for meta-analysis is small [23]. This may have been another source of heterogeneity. Third, in our review process, we did not distinguish between studies on first-ever stroke and those on recurrent stroke, which may be another source of heterogeneity in the meta-analyses. We should also consider that I², which indicates heterogeneity in the results of meta-analyses, has the risk of being a biased estimate in small meta-analyses [88].

Physicians should consider RAT as a therapeutic option to facilitate functional recovery after stroke, as high-level evidence supports the superiority of RAT over CT. Despite the significant heterogeneity, the generalizability of the effect sizes from the meta-analysis was still considered valid because the meta-analysis was conducted using a random-effects model. The results of this meta-analysis will be updated in future studies. We propose that future studies should consider the factors that may cause heterogeneity in the results of the metaanalysis more comprehensively. In addition, it is necessary to consider a valid methodology that accounts for the heterogeneity of interventions and outcome measures in rehabilitation medicine, which is a barrier to meta-analysis and must be overcome to determine the generalized effectiveness of rehabilitative therapies.

SUPPLEMENTARY MATERIAL

Supplementary Table 1

Characteristics of included studies

Click here to view

REFERENCES

1. Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd-Allah F, Abera SF, Aboyans V, Abraham JP, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NM, Achoki T, Ackerman IN, Ademi Z, Adou AK, Adsuar JC, Afshin A, Agardh EE, Alam SS, Alasfoor D, Albittar MI, Alegretti MA, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Alla F, Allebeck P, Almazroa MA, Alsharif U, Alvarez E, Alvis-Guzman N, Amare AT, Ameh EA, Amini H, Ammar W, Anderson HR, Anderson BO, Antonio CA, Anwari P, Arnlöv J, Arsic Arsenijevic VS, Artaman A, Asghar RJ, Assadi R, Atkins LS, Avila MA, Awuah B, Bachman VF, Badawi A, Bahit MC, Balakrishnan K, Banerjee A, Barker-Collo SL, Barquera S, Barregard L, Barrero LH, Basu A, Basu S, Basulaiman MO, Beardsley J, Bedi N, Beghi E, Bekele T, Bell ML, Benjet C, Bennett DA, Bensenor IM, Benzian H, Bernabé E, Bertozzi-Villa A, Beyene TJ, Bhala N, Bhalla A, Bhutta ZA, Bienhoff K, Bikbov B, Biryukov S, Blore JD, Blosser CD, Blyth FM, Bohensky MA, Bolliger IW, Bora Başara B, Bornstein NM, Bose D, Boufous S, Bourne RR, Boyers LN, Brainin M, Brayne CE, Brazinova A, Breitborde NJ, Brenner H, Briggs AD, Brooks PM, Brown JC, Brugha TS, Buchbinder R, Buckle GC, Budke CM, Bulchis A, Bulloch AG, Campos-Nonato IR, Carabin H, Carapetis JR, Cárdenas R, Carpenter DO, Caso V, Castañeda-Orjuela CA, Castro RE, Catalá-López F, Cavalleri F, Çavlin A, Chadha VK, Chang JC, Charlson FJ, Chen H, Chen W, Chiang PP, Chimed-Ochir O, Chowdhury R, Christensen H, Christophi CA, Cirillo M, Coates MM, Coffeng LE, Coggeshall MS, Colistro V, Colquhoun SM, Cooke GS, Cooper C, Cooper LT, Coppola LM,



Cortinovis M, Criqui MH, Crump JA, Cuevas-Nasu L, Danawi H, Dandona L, Dandona R, Dansereau E, Dargan PI, Davey G, Davis A, Davitoiu DV, Dayama A, De Leo D, Degenhardt L, Del Pozo-Cruz B, Dellavalle RP, Deribe K, Derrett S, Des Jarlais DC, Dessalegn M, Dharmaratne SD, Dherani MK, Diaz-Torné C, Dicker D, Ding EL, Dokova K, Dorsey ER, Driscoll TR, Duan L, Duber HC, Ebel BE, Edmond KM, Elshrek YM, Endres M, Ermakov SP, Erskine HE, Eshrati B, Esteghamati A, Estep K, Faraon EJ, Farzadfar F, Fay DF, Feigin VL, Felson DT, Fereshtehnejad SM, Fernandes JG, Ferrari AJ, Fitzmaurice C, Flaxman AD, Fleming TD, Foigt N, Forouzanfar MH, Fowkes FG, Paleo UF, Franklin RC, Fürst T, Gabbe B, Gaffikin L, Gankpé FG, Geleijnse JM, Gessner BD, Gething P, Gibney KB, Giroud M, Giussani G, Gomez Dantes H, Gona P, González-Medina D, Gosselin RA, Gotay CC, Goto A, Gouda HN, Graetz N, Gugnani HC, Gupta R, Gupta R, Gutiérrez RA, Haagsma J, Hafezi-Nejad N, Hagan H, Halasa YA, Hamadeh RR, Hamavid H, Hammami M, Hancock J, Hankey GJ, Hansen GM, Hao Y, Harb HL, Haro JM, Havmoeller R, Hay SI, Hay RJ, Heredia-Pi IB, Heuton KR, Heydarpour P, Higashi H, Hijar M, Hoek HW, Hoffman HJ, Hosgood HD, Hossain M, Hotez PJ, Hoy DG, Hsairi M, Hu G, Huang C, Huang JJ, Husseini A, Huynh C, Iannarone ML, Iburg KM, Innos K, Inoue M, Islami F, Jacobsen KH, Jarvis DL, Jassal SK, Jee SH, Jeemon P, Jensen PN, Jha V, Jiang G, Jiang Y, Jonas JB, Juel K, Kan H, Karch A, Karema CK, Karimkhani C, Karthikeyan G, Kassebaum NJ, Kaul A, Kawakami N, Kazanjan K, Kemp AH, Kengne AP, Keren A, Khader YS, Khalifa SE, Khan EA, Khan G, Khang YH, Kieling C, Kim D, Kim S, Kim Y, Kinfu Y, Kinge JM, Kivipelto M, Knibbs LD, Knudsen AK, Kokubo Y, Kosen S, Krishnaswami S, Kuate Defo B, Kucuk Bicer B, Kuipers EJ, Kulkarni C, Kulkarni VS, Kumar GA, Kyu HH, Lai T, Lalloo R, Lallukka T, Lam H, Lan Q, Lansingh VC, Larsson A, Lawrynowicz AE, Leasher JL, Leigh J, Leung R, Levitz CE, Li B, Li Y, Li Y, Lim SS, Lind M, Lipshultz SE, Liu S, Liu Y, Lloyd BK, Lofgren KT, Logroscino G, Looker KJ, Lortet-Tieulent J, Lotufo PA, Lozano R, Lucas RM, Lunevicius R, Lyons RA, Ma S, Macintyre MF, Mackay MT, Majdan M, Malekzadeh R, Marcenes W, Margolis DJ, Margono C, Marzan MB, Masci JR, Mashal MT, Matzopoulos R, Mayosi BM, Mazorodze TT, Mcgill NW, Mcgrath JJ, Mckee M, Mclain A, Meaney PA, Medina C, Mehndiratta MM, Mekonnen W, Melaku YA, Meltzer M, Memish ZA, Mensah GA, Meretoja A, Mhimbira FA, Micha R, Miller TR, Mills EJ, Mitchell PB, Mock CN, Mohamed Ibrahim N, Mohammad KA, Mokdad AH, Mola GL, Monasta L, Montañez Hernandez JC, Montico M, Montine TJ, Mooney MD, Moore AR, Moradi-Lakeh M, Moran AE, Mori R, Moschandreas J, Moturi WN, Moyer ML, Mozaffarian D, Msemburi WT, Mueller UO, Mukaigawara M, Mullany EC, Murdoch ME, Murray J, Murthy KS, Naghavi M, Naheed A, Naidoo KS, Naldi L, Nand D, Nangia V, Narayan KM, Nejjari C, Neupane SP, Newton CR, Ng M, Ngalesoni FN, Nguyen G, Nisar MI, Nolte S, Norheim OF, Norman RE, Norrving B, Nyakarahuka L, Oh IH, Ohkubo T, Ohno SL, Olusanya BO, Opio JN, Ortblad K, Ortiz A, Pain AW, Pandian JD, Panelo CI, Papachristou C, Park EK, Park JH, Patten SB, Patton GC, Paul VK, Pavlin BI, Pearce N, Pereira DM, Perez-Padilla R, Perez-Ruiz F, Perico N, Pervaiz A, Pesudovs K, Peterson CB, Petzold M, Phillips MR, Phillips BK, Phillips DE, Piel FB, Plass D, Poenaru D, Polinder S, Pope D, Popova S, Poulton RG, Pourmalek F, Prabhakaran D, Prasad NM, Pullan RL, Qato DM, Quistberg DA, Rafay A, Rahimi K, Rahman SU, Raju M, Rana SM, Razavi H, Reddy KS, Refaat A, Remuzzi G, Resnikoff S, Ribeiro AL, Richardson L, Richardus JH, Roberts DA, Rojas-Rueda D, Ronfani L, Roth GA, Rothenbacher D, Rothstein DH, Rowley JT, Roy N, Ruhago GM, Saeedi MY, Saha S, Sahraian MA, Sampson UK, Sanabria JR, Sandar L, Santos IS, Satpathy M, Sawhney M, Scarborough P, Schneider IJ, Schöttker B, Schumacher AE, Schwebel DC, Scott JG, Seedat S, Sepanlou SG, Serina PT, Servan-Mori EE, Shackelford KA, Shaheen A, Shahraz S, Shamah Levy T, Shangguan S, She J, Sheikhbahaei S, Shi P, Shibuya K, Shinohara Y, Shiri R, Shishani K, Shiue I, Shrime MG, Sigfusdottir ID, Silberberg DH, Simard EP, Sindi S, Singh A, Singh JA, Singh L, Skirbekk V, Slepak EL, Sliwa K, Soneji S, Søreide K, Soshnikov S, Sposato LA, Sreeramareddy CT, Stanaway JD, Stathopoulou V, Stein DJ, Stein MB, Steiner C, Steiner TJ, Stevens A, Stewart A, Stovner LJ, Stroumpoulis K, Sunguya BF, Swaminathan S, Swaroop M, Sykes BL, Tabb KM, Takahashi K, Tandon N, Tanne D, Tanner M, Tavakkoli M, Taylor HR, Te Ao BJ, Tediosi F, Temesgen AM, Templin T, Ten Have M, Tenkorang EY, Terkawi AS, Thomson B, Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tonelli M, Topouzis F, Toyoshima H, Traebert J, Tran BX, Trillini M, Truelsen T, Tsilimbaris M, Tuzcu EM, Uchendu US, Ukwaja KN, Undurraga EA, Uzun SB, Van Brakel WH, Van De Vijver S, van Gool CH, Van Os J, Vasankari TJ, Venketasubramanian N, Violante FS, Vlassov VV, Vollset SE, Wagner GR, Wagner J, Waller SG, Wan X, Wang H, Wang J, Wang L, Warouw TS, Weichenthal S, Weiderpass E, Weintraub RG, Wenzhi W, Werdecker A, Westerman R, Whiteford HA, Wilkinson JD, Williams TN, Wolfe CD, Wolock TM, Woolf AD, Wulf S, Wurtz B, Xu G, Yan LL, Yano Y, Ye P, Yentür GK, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu C, Zaki ME, Zhao Y, Zheng Y, Zonies D, Zou X, Salomon JA, Lopez AD, Vos T; GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 2015;386:2145-2191. PUBMED | CROSSREF

 Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro



KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128. PUBMED | CROSSREF

3. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gonzalez-Medina D, Gosselin R, Grainger R, Grant B, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, AlMazroa MA, Memish ZA. Disabilityadjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-2223. PUBMED | CROSSREF



- 4. Nijland RH, van Wegen EE, Harmeling-van der Wel BC, Kwakkel G; EPOS Investigators. Presence of finger extension and shoulder abduction within 72 hours after stroke predicts functional recovery: early prediction of functional outcome after stroke: the EPOS cohort study. Stroke 2010;41:745-750. PUBMED | CROSSREF
- Kwakkel G, Kollen BJ, van der Grond J, Prevo AJ. Probability of regaining dexterity in the flaccid upper limb: impact of severity of paresis and time since onset in acute stroke. Stroke 2003;34:2181-2186.
 PUBMED | CROSSREF
- Jørgensen HS, Nakayama H, Raaschou HO, Olsen TS. Recovery of walking function in stroke patients: the Copenhagen Stroke Study. Arch Phys Med Rehabil 1995;76:27-32.
 PUBMED | CROSSREF
- Duret C, Grosmaire AG, Krebs HI. Robot-assisted therapy in upper extremity hemiparesis: overview of an evidence-based approach. Front Neurol 2019;10:412.
 PUBMED I CROSSREF
- Bertani R, Melegari C, De Cola MC, Bramanti A, Bramanti P, Calabrò RS. Effects of robot-assisted upper limb rehabilitation in stroke patients: a systematic review with meta-analysis. Neurol Sci 2017;38:1561:1569.
 PUBMED | CROSSREF
- Kwakkel G, Kollen BJ, Krebs HI. Effects of robot-assisted therapy on upper limb recovery after stroke: a systematic review. Neurorehabil Neural Repair 2008;22:111-121.
 PUBMED | CROSSREF
- Veerbeek JM, Langbroek-Amersfoort AC, van Wegen EE, Meskers CG, Kwakkel G. Effects of robot-assisted therapy for the upper limb after stroke. Neurorehabil Neural Repair 2017;31:107-121.
 PUBMED | CROSSREF
- Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. Cochrane Database Syst Rev 2018;9:CD006876.
 PUBMED | CROSSREF
- Chen Z, Wang C, Fan W, Gu M, Yasin G, Xiao S, Huang J, Huang X. Robot-assisted arm training versus therapist-mediated training after stroke: a systematic review and meta-analysis. J Healthc Eng 2020;2020:8810867.
 PUBMED | CROSSREF
- Moucheboeuf G, Griffier R, Gasq D, Glize B, Bouyer L, Dehail P, Cassoudesalle H. Effects of robotic gait training after stroke: a meta-analysis. Ann Phys Rehabil Med 2020;63:518-534.
 PUBMED | CROSSREF
- Mehrholz J, Thomas S, Kugler J, Pohl M, Elsner B. Electromechanical-assisted training for walking after stroke. Cochrane Database Syst Rev 2020;10:CD006185.
- Wang L, Zheng Y, Dang Y, Teng M, Zhang X, Cheng Y, Zhang X, Yu Q, Yin A, Lu X. Effects of robotassisted training on balance function in patients with stroke: A systematic review and meta-analysis. J Rehabil Med 2021;53:jrm00174.
 PUBMED | CROSSREF
- 16. Warutkar V, Dadgal R, Mangulkar UR. Use of robotics in gait rehabilitation following stroke: a review. Cureus 2022;14:e31075.
 - PUBMED | CROSSREF
- Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. Cochrane Database Syst Rev 2018;9:CD006876.
 PUBMED | CROSSREF
- Kim DY, Ryu B, Oh BM, Kim DY, Kim DS, Kim DY, Kim DK, Kim EJ, Lee HY, Choi H, Kim HS, Lee HH, Kim HJ, Oh HM, Seok H, Park J, Park J, Park JG, Kim JM, Lee J, Shin JH, Lee JK, Oh JS, Park KD, Kim KT, Chang MC, Chun MH, Kim MW, Kang MG, Song MK, Choi M, Ko MH, Kim NY, Paik NJ, Jung SH, Yoon SY, Lim SH, Lee SJ, Yoo SD, Lee SH, Yang SN, Park SW, Lee SY, Han SJ, Lee SJ, Bok SK, Ohn SH, Im S, Pyun SB, Hyun SE, Kim SH, Ko SH, Jee S, Kwon S, Kim TW, Chang WH, Chang WK, Yoo WK, Kim YH, Yoo YJ, Kim YW, Shin YI, Park YG, Choi YH, Kim Y; KSNR Stroke CPG Writing Group. Clinical Practice Guideline for Stroke Rehabilitation in Korea-Part 1: rehabilitation for motor function (2022). Brain Neurorehabil 2023;16:e18.
- Lim CY, In J. Considerations for crossover design in clinical study. Korean J Anesthesiol 2021;74:293-299.
 PUBMED | CROSSREF
- 20. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549. PUBMED | CROSSREF



21. Teasell R, Salbach NM, Foley N, Mountain A, Cameron JI, de Jong A, Acerra NE, Bastasi D, Carter SL, Fung J, Halabi ML, Iruthayarajah J, Harris J, Kim E, Noland A, Pooyania S, Rochette A, Stack BD, Symcox E, Timpson D, Varghese S, Verrilli S, Gubitz G, Casaubon LK, Dowlatshahi D, Lindsay MP. Canadian stroke best practice recommendations: rehabilitation, recovery, and community participation following stroke. Part one: rehabilitation and recovery following stroke; 6th edition update 2019. Int J Stroke 2020;15:763-788.

PUBMED | CROSSREF

- 22. Kim DY, Kim YH, Lee J, Chang WH, Kim MW, Pyun SB, Yoo WK, Ohn SH, Park KD, Oh BM, Lim SH, Jung KJ, Ryu BJ, Im S, Jee SJ, Seo HG, Rah UW, Park JH, Sohn MK, Chun MH, Shin HS, Lee SJ, Lee YS, Park SW, Park YG, Paik NJ, Lee SG, Lee JK, Koh SE, Kim DK, Park GY, Shin Y, Ko MH, Kim YW, Yoo SD, Kim EJ, Oh MK, Chang JH, Jung SH, Kim TW, Kim WS, Kim DH, Park TH, Lee KS, Hwang BY, Song YJ. Clinical Practice Guideline for Stroke Rehabilitation in Korea 2016. Brain Neurorehabil 2017;10:e11. CROSSREF
- 23. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester: John Wiley & Sons; 2019.
- 24. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-394.
 PUBMED | CROSSREF
- Villafañe JH, Taveggia G, Galeri S, Bissolotti L, Mullè C, Imperio G, Valdes K, Borboni A, Negrini S. Efficacy of short-term robot-assisted rehabilitation in patients with hand paralysis after stroke: a randomized clinical trial. Hand (N Y) 2018;13:95-102.
 PUBMED | CROSSREF
- Lee KW, Kim SB, Lee JH, Lee SJ, Yoo SW. Effect of upper extremity robot-assisted exercise on spasticity in stroke patients. Ann Rehabil Med 2016;40:961-971.
 PUBMED | CROSSREF
- Lum PS, Burgar CG, Shor PC, Majmundar M, Van der Loos M. Robot-assisted movement training compared with conventional therapy techniques for the rehabilitation of upper-limb motor function after stroke. Arch Phys Med Rehabil 2002;83:952-959.
 PUBMED | CROSSREF
- Lum PS, Burgar CG, Van der Loos M, Shor PC, Majmundar M, Yap R. MIME robotic device for upper-limb neurorehabilitation in subacute stroke subjects: a follow-up study. J Rehabil Res Dev 2006;43:631-642.
 PUBMED | CROSSREF
- Lo AC, Guarino PD, Richards LG, Haselkorn JK, Wittenberg GF, Federman DG, Ringer RJ, Wagner TH, Krebs HI, Volpe BT, Bever CT Jr, Bravata DM, Duncan PW, Corn BH, Maffucci AD, Nadeau SE, Conroy SS, Powell JM, Huang GD, Peduzzi P. Robot-assisted therapy for long-term upper-limb impairment after stroke. N Engl J Med 2010;362:1772-1783.
 PUBMED | CROSSREF
- Frisoli A, Barsotti M, Sotgiu E, Lamola G, Procopio C, Chisari C. A randomized clinical control study on the efficacy of three-dimensional upper limb robotic exoskeleton training in chronic stroke. J Neuroeng Rehabil 2022;19:14.
 PUBMED | CROSSREF
- Kim JH, Ko MH, Park JW, Lee HJ, Nam KY, Nam YG, Oh CH, Park JH, Kwon BS. Efficacy of electromechanically-assisted rehabilitation of upper limb function in post-stroke patients: a randomized controlled study. J Rehabil Med Clin Commun 2021;4:1000074.
- Budhota A, Chua KS, Hussain A, Kager S, Cherpin A, Contu S, Vishwanath D, Kuah CW, Ng CY, Yam LH, Loh YJ, Rajeswaran DK, Xiang L, Burdet E, Campolo D. Robotic assisted upper limb training post stroke: a randomized control trial using combinatory approach toward reducing workforce demands. Front Neurol 2021;12:622014.
 PUBMED | CROSSREF
- 33. Rémy-Néris O, Le Jeannic A, Dion A, Médée B, Nowak E, Poiroux É, Durand-Zaleski I, Beis JM, Bensmaïl D, Benaim C, Luaute J, Bonan I, Boyer F, Coudeyre E, Daviet JC, Dehail P, Ferrapie AL, Isambert JL, Kerdraon J, Marque P, Froger J, Allart E, Gross R, Yelnik A, Bensoussan L, Tasseel-Ponche S; REM Investigative Team. Additional, mechanized upper limb self-rehabilitation in patients with subacute stroke: the REM-AVC randomized trial. Stroke 2021;52:1938-1947.
- Ranzani R, Lambercy O, Metzger JC, Califfi A, Regazzi S, Dinacci D, Petrillo C, Rossi P, Conti FM, Gassert R. Neurocognitive robot-assisted rehabilitation of hand function: a randomized control trial on motor recovery in subacute stroke. J Neuroeng Rehabil 2020;17:115.
 PUBMED | CROSSREF



- 35. Xu Q, Li C, Pan Y, Li W, Jia T, Li Z, Ma D, Pang X, Ji L. Impact of smart force feedback rehabilitation robot training on upper limb motor function in the subacute stage of stroke. NeuroRehabilitation 2020;47:209-215. PUBMED | CROSSREF
- 36. Franceschini M, Mazzoleni S, Goffredo M, Pournajaf S, Galafate D, Criscuolo S, Agosti M, Posteraro F. Upper limb robot-assisted rehabilitation versus physical therapy on subacute stroke patients: a follow-up study. J Bodyw Mov Ther 2020;24:194-198.
 PUBMED | CROSSREF
- Orihuela-Espina F, Roldán GF, Sánchez-Villavicencio I, Palafox L, Leder R, Sucar LE, Hernández-Franco J. Robot training for hand motor recovery in subacute stroke patients: a randomized controlled trial. J Hand Ther 2016;29:51-57.
- PUBMED | CROSSREF
- Aprile I, Germanotta M, Cruciani A, Loreti S, Pecchioli C, Cecchi F, Montesano A, Galeri S, Diverio M, Falsini C, Speranza G, Langone E, Papadopoulou D, Padua L, Carrozza MC; FDG Robotic Rehabilitation Group. Upper limb robotic rehabilitation after stroke: a multicenter, randomized clinical trial. J Neurol Phys Ther 2020;44:3-14.
 PUBMED | CROSSREF
- Dehem S, Gilliaux M, Stoquart G, Detrembleur C, Jacquemin G, Palumbo S, Frederick A, Lejeune T. Effectiveness of upper-limb robotic-assisted therapy in the early rehabilitation phase after stroke: a singleblind, randomised, controlled trial. Ann Phys Rehabil Med 2019;62:313-320.
 PUBMED | CROSSREF
- Calabrò RS, Accorinti M, Porcari B, Carioti L, Ciatto L, Billeri L, Andronaco VA, Galletti F, Filoni S, Naro A. Does hand robotic rehabilitation improve motor function by rebalancing interhemispheric connectivity after chronic stroke? Encouraging data from a randomised-clinical-trial. Clin Neurophysiol 2019;130:767-780.
 PUBMED | CROSSREF
- Masiero S, Armani M, Ferlini G, Rosati G, Rossi A. Randomized trial of a robotic assistive device for the upper extremity during early inpatient stroke rehabilitation. Neurorehabil Neural Repair 2014;28:377-386.
 PUBMED | CROSSREF
- Rodgers H, Bosomworth H, Krebs HI, van Wijck F, Howel D, Wilson N, Aird L, Alvarado N, Andole S, Cohen DL, Dawson J, Fernandez-Garcia C, Finch T, Ford GA, Francis R, Hogg S, Hughes N, Price CI, Ternent L, Turner DL, Vale L, Wilkes S, Shaw L. Robot assisted training for the upper limb after stroke (RATULS): a multicentre randomised controlled trial. Lancet 2019;394:51-62.
 PUBMED | CROSSREF
- Sale P, Mazzoleni S, Lombardi V, Galafate D, Massimiani MP, Posteraro F, Damiani C, Franceschini M. Recovery of hand function with robot-assisted therapy in acute stroke patients: a randomized-controlled trial. Int J Rehabil Res 2014;37:236-242.
 PUBMED | CROSSREF
- 44. Timmermans AA, Lemmens RJ, Monfrance M, Geers RP, Bakx W, Smeets RJ, Seelen HA. Effects of task-oriented robot training on arm function, activity, and quality of life in chronic stroke patients: a randomized controlled trial. J Neuroeng Rehabil 2014;11:45. PUBMED | CROSSREF
- 45. Wu CY, Yang CL, Chuang LL, Lin KC, Chen HC, Chen MD, Huang WC. Effect of therapist-based versus robot-assisted bilateral arm training on motor control, functional performance, and quality of life after chronic stroke: a clinical trial. Phys Ther 2012;92:1006-1016. PUBMED | CROSSREF
- Liao WW, Wu CY, Hsieh YW, Lin KC, Chang WY. Effects of robot-assisted upper limb rehabilitation on daily function and real-world arm activity in patients with chronic stroke: a randomized controlled trial. Clin Rehabil 2012;26:111-120.
 PUBMED | CROSSREF
- Masiero S, Armani M, Rosati G. Upper-limb robot-assisted therapy in rehabilitation of acute stroke patients: focused review and results of new randomized controlled trial. J Rehabil Res Dev 2011;48:355-366.
 PUBMED | CROSSREF
- Housman SJ, Scott KM, Reinkensmeyer DJ. A randomized controlled trial of gravity-supported, computer-enhanced arm exercise for individuals with severe hemiparesis. Neurorehabil Neural Repair 2009;23:505-514.
 PUBMED | CROSSREF
- 49. Masiero S, Celia A, Rosati G, Armani M. Robotic-assisted rehabilitation of the upper limb after acute stroke. Arch Phys Med Rehabil 2007;88:142-149.
 PUBMED | CROSSREF



- Zhai X, Wu Q, Li X, Xu Q, Zhang Y, Fan S, Zhang LQ, Pan Y. Effects of robot-aided rehabilitation on the ankle joint properties and balance function in stroke survivors: a randomized controlled trial. Front Neurol 2021;12:719305.
 PUBMED | CROSSREF
- Yeung LF, Lau CC, Lai CW, Soo YO, Chan ML, Tong RK. Effects of wearable ankle robotics for stair and over-ground training on sub-acute stroke: a randomized controlled trial. J Neuroeng Rehabil 2021;18:19.
 PUBMED | CROSSREF
- 52. Kim SY, Yang L, Park JJ, Kim EJ, JoshuaPark MS, You SH, Kim YH, Ko HY, Shin YI. Il. Effects of innovative WALKBOT robotic-assisted locomotor training on balance and gait recovery in hemiparetic stroke: a prospective, randomized, experimenter blinded case control study with a four-week follow-up. IEEE Trans Neural Syst Rehabil Eng 2015;23:636-642. PUBMED | CROSSREF
- 53. Ochi M, Wada F, Saeki S, Hachisuka K. Gait training in subacute non-ambulatory stroke patients using a full weight-bearing gait-assistance robot: a prospective, randomized, open, blinded-endpoint trial. J Neurol Sci 2015;353:130-136.
 PURMED I CROSSREE
- 54. Schwartz I, Sajin A, Fisher I, Neeb M, Shochina M, Katz-Leurer M, Meiner Z. The effectiveness of locomotor therapy using robotic-assisted gait training in subacute stroke patients: a randomized controlled trial. PM R 2009;1:516-523. PUBMED | CROSSREF
- 55. Hornby TG, Campbell DD, Kahn JH, Demott T, Moore JL, Roth HR. Enhanced gait-related improvements after therapist- versus robotic-assisted locomotor training in subjects with chronic stroke: a randomized controlled study. Stroke 2008;39:1786-1792.
 PUBMED | CROSSREF
- 56. Palmcrantz S, Wall A, Vreede KS, Lindberg P, Danielsson A, Sunnerhagen KS, Häger CK, Borg J. Impact of intensive gait training with and without electromechanical assistance in the chronic phase after stroke-a multi-arm randomized controlled trial with a 6 and 12 months follow up. Front Neurosci 2021;15:660726. PUBMED | CROSSREF
- 57. Jayaraman A, O'Brien MK, Madhavan S, Mummidisetty CK, Roth HR, Hohl K, Tapp A, Brennan K, Kocherginsky M, Williams KJ, Takahashi H, Rymer WZ. Stride management assist exoskeleton vs functional gait training in stroke: A randomized trial. Neurology 2019;92:e263-e273. PUBMED | CROSSREF
- Nam YG, Park JW, Lee HJ, Nam KY, Choi MR, Yu CS, Zhu L, Zhang X, Lee JW, Kwon BS. Further effects of electromechanically assisted gait trainer (Exowalk®) in patients with chronic stroke: a randomized controlled trial. J Rehabil Med 2020;52:jrm00097.
- 59. Wall A, Borg J, Vreede K, Palmcrantz S. A randomized controlled study incorporating an electromechanical gait machine, the Hybrid Assistive Limb, in gait training of patients with severe limitations in walking in the subacute phase after stroke. PLoS One 2020;15:e0229707.
 PUBMED | CROSSREF
- Park C, Oh-Park M, Dohle C, Bialek A, Friel K, Edwards D, Krebs HI, You JS. Effects of innovative hipknee-ankle interlimb coordinated robot training on ambulation, cardiopulmonary function, depression, and fall confidence in acute hemiplegia. NeuroRehabilitation 2020;46:577-587.
 PUBMED | CROSSREF
- Kim J, Kim DY, Chun MH, Kim SW, Jeon HR, Hwang CH, Choi JK, Bae S. Effects of robot-(Morning Walk[®]) assisted gait training for patients after stroke: a randomized controlled trial. Clin Rehabil 2019;33:516-523.
 PUBMED | CROSSREF
- 62. Nam YG, Lee JW, Park JW, Lee HJ, Nam KY, Park JH, Yu CS, Choi MR, Kwon BS. Effects of electromechanical exoskeleton-assisted gait training on walking ability of stroke patients: a randomized controlled trial. Arch Phys Med Rehabil 2019;100:26-31. PUBMED | CROSSREF
- 63. Belas Dos Santos M, Barros de Oliveira C, Dos Santos A, Garabello Pires C, Dylewski V, Arida RM. A comparative study of conventional physiotherapy versus robot-assisted gait training associated to physiotherapy in individuals with ataxia after stroke. Behav Neurol 2018;2018:2892065. PUBMED | CROSSREF
- Chua J, Culpan J, Menon E. Efficacy of an electromechanical gait trainer poststroke in singapore: a randomized controlled trial. Arch Phys Med Rehabil 2016;97:683-690.
 PUBMED | CROSSREF



- 65. Taveggia G, Borboni A, Mulé C, Villafañe JH, Negrini S. Conflicting results of robot-assisted versus usual gait training during postacute rehabilitation of stroke patients: a randomized clinical trial. Int J Rehabil Res 2016;39:29-35.
 PUBMED | CROSSREF
- 66. Klamroth-Marganska V, Blanco J, Campen K, Curt A, Dietz V, Ettlin T, Felder M, Fellinghauer B, Guidali M, Kollmar A, Luft A, Nef T, Schuster-Amft C, Stahel W, Riener R. Three-dimensional, task-specific robot therapy of the arm after stroke: a multicentre, parallel-group randomised trial. Lancet Neurol 2014;13:159-166. PUBMED | CROSSREF
- 67. Kutner NG, Zhang R, Butler AJ, Wolf SL, Alberts JL. Quality-of-life change associated with roboticassisted therapy to improve hand motor function in patients with subacute stroke: a randomized clinical trial. Phys Ther 2010;90:493-504.
 PUBMED | CROSSREF
- Esquenazi A, Lee S, Watanabe T, Nastaskin A, McKee C, O'Neill J, Scheponik K, May J. A comparison of the Armeo to Tabletop-assisted therapy exercises as supplemental interventions in acute stroke rehabilitation: a randomized single blind study. PM R 2021;13:30-37.
 PUBMED | CROSSREF
- 69. Wu CY, Yang CL, Chen MD, Lin KC, Wu LL. Unilateral versus bilateral robot-assisted rehabilitation on arm-trunk control and functions post stroke: a randomized controlled trial. J Neuroeng Rehabil 2013;10:35.
 PUBMED | CROSSREF
- 70. Yu D, Yang Z, Lei L, Chaoming N, Ming W. Robot-assisted gait training plan for patients in poststroke recovery period: a single blind randomized controlled trial. BioMed Res Int 2021;2021:5820304. PUBMED | CROSSREF
- Li DX, Zha FB, Long JJ, Liu F, Cao J, Wang YL. Effect of robot assisted gait training on motor and walking function in patients with subacute stroke: a random controlled study. J Stroke Cerebrovasc Dis 2021;30:105807.

PUBMED | CROSSREF

- 72. Li Y, Fan T, Qi Q, Wang J, Qiu H, Zhang L, Wu X, Ye J, Chen G, Long J, Wang Y, Huang G, Li J. Efficacy of a novel exoskeletal robot for locomotor rehabilitation in stroke patients: a multi-center, non-inferiority, randomized controlled trial. Front Aging Neurosci 2021;13:706569.
 PUBMED | CROSSREF
- 73. Lewandowska-Sroka P, Stabrawa R, Kozak D, Poświata A, Łysoń-Uklańska B, Bienias K, Roksela A, Kliś M, Mikulski M. The influence of EMG-triggered robotic movement on walking, muscle force and spasticity after an ischemic stroke. Medicina (Kaunas) 2021;57:227.
 PUBMED | CROSSREF
- 74. Alingh JF, Fleerkotte BM, Groen BE, Rietman JS, Weerdesteyn V, van Asseldonk EH, Geurts AC, Buurke JH. Effect of assist-as-needed robotic gait training on the gait pattern post stroke: a randomized controlled trial. J Neuroeng Rehabil 2021;18:26.
 PUBMED | CROSSREF
- 75. Tomida K, Sonoda S, Hirano S, Suzuki A, Tanino G, Kawakami K, Saitoh E, Kagaya H. Randomized controlled trial of gait training using gait exercise assist robot (GEAR) in stroke patients with hemiplegia. J Stroke Cerebrovasc Dis 2019;28:2421-2428.
 PUBMED | CROSSREF
- 76. Tanaka N, Matsushita S, Sonoda Y, Maruta Y, Fujitaka Y, Sato M, Simomori M, Onaka R, Harada K, Hirata T, Kinoshita S, Okamoto T, Okamura H. Effect of stride management assist gait training for poststroke hemiplegia: a single center, open-label, randomized controlled trial. J Stroke Cerebrovasc Dis 2019;28:477-486.

PUBMED | CROSSREF

 Mayr A, Quirbach E, Picelli A, Kofler M, Smania N, Saltuari L. Early robot-assisted gait retraining in non-ambulatory patients with stroke: a single blind randomized controlled trial. Eur J Phys Rehabil Med 2018;54:819-826.

PUBMED

- 78. Watanabe H, Goto R, Tanaka N, Matsumura A, Yanagi H. Effects of gait training using the Hybrid Assistive Limb® in recovery-phase stroke patients: A 2-month follow-up, randomized, controlled study. NeuroRehabilitation 2017;40:363-367. PUBMED | CROSSREF
- 79. Kelley CP, Childress J, Boake C, Noser EA. Over-ground and robotic-assisted locomotor training in adults with chronic stroke: a blinded randomized clinical trial. Disabil Rehabil Assist Technol 2013;8:161-168. PUBMED | CROSSREF



- Hidler J, Nichols D, Pelliccio M, Brady K, Campbell DD, Kahn JH, Hornby TG. Multicenter randomized clinical trial evaluating the effectiveness of the Lokomat in subacute stroke. Neurorehabil Neural Repair 2009;23:5-13.
 PUBMED | CROSSREF
- Molteni F, Guanziroli E, Goffredo M, Calabrò RS, Pournajaf S, Gaffuri M, Gasperini G, Filoni S, Baratta S, Galafate D, Le Pera D, Bramanti P, Franceschini M; On Behalf Of Italian Eksogait Study Group. Gait recovery with an overground powered exoskeleton: a randomized controlled trial on subacute stroke subjects. Brain Sci 2021;11:104.
 PUBMED | CROSSREF
- Rojek A, Mika A, Oleksy Ł, Stolarczyk A, Kielnar R. Effects of exoskeleton gait training on balance, load distribution, and functional status in stroke: a randomized controlled trial. Front Neurol 2020;10:1344.
 PUBMED | CROSSREF
- Yang X, Shi X, Xue X, Deng Z. Efficacy of robot-assisted training on rehabilitation of upper limb function in patients with stroke: a systematic review and meta-analysis. Arch Phys Med Rehabil 2023;104:1498-1513.
 PUBMED | CROSSREF
- 84. Bamman MM, Cutter GR, Brienza DM, Chae J, Corcos DM, DeLuca S, Field-Fote E, Fouad MN, Lang CE, Lindblad A, Motl RW, Perna CG, Reisman D, Saag KM, Savitz SI, Schmitz KH, Stevens-Lapsley J, Whyte J, Winstein CJ, Michel ME. Medical rehabilitation: guidelines to advance the field with high-impact clinical trials. Arch Phys Med Rehabil 2018;99:2637-2648. PUBMED | CROSSREF
- 85. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HC. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 2010;63:737-745. PUBMED | CROSSREF
- 86. Whiteneck G, Dijkers MP. Difficult to measure constructs: conceptual and methodological issues concerning participation and environmental factors. Arch Phys Med Rehabil 2009;90 Suppl:S22-S35.
 PUBMED | CROSSREF
- 87. Kramer P, Grampurohit N. Hinojosa and Kramer's evaluation in occupational therapy: obtaining and interpreting data. 5th ed. North Bethesda, MD: American Occupational Therapy Association; 2020.
- 88. von Hippel PT. The heterogeneity statistic I(²) can be biased in small meta-analyses. BMC Med Res Methodol 2015;15:35.
 PUBMED | CROSSREF